GlobeNewswire - Industry News on Biotechnology Contains the last 20 releases uuid:53fa8735-38a8-4f71-92c4-c820a69bbc05;id=2800 2021-03-02T22:16:56Z newsdesk@globenewswire.com (NewsDesk) http://www.yebxqs.cn/LegacyRss?Length=4 newsdesk@globenewswire.com http://www.yebxqs.cn/news-release/2021/03/02/2185758/0/en/Rezolute-to-Participate-in-Upcoming-Investor-Conferences-in-March.html Rezolute to Participate in Upcoming Investor Conferences in March 2021-03-02T22:16:56Z 2021-03-03T02:16:58Z REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company’s CEO and Founder, will be presenting at the following upcoming investor conferences:

]]>
2185758 en GlobeNewswire Inc. Rezolute Inc. Tue, 02 Mar 2021 22:17 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/03/02/2185736/0/en/Pacific-Biosciences-Grants-Equity-Incentive-Award-to-New-Employee.html Pacific Biosciences Grants Equity Incentive Award to New Employee 2021-03-02T21:30:00Z 2021-03-03T02:16:58Z MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 40,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on February 25, 2021.

]]>
2185736 en GlobeNewswire Inc. Pacific Biosciences of California, Inc. Tue, 02 Mar 2021 21:30 GMT Health Stock Market News
http://www.yebxqs.cn/news-release/2021/03/02/2185725/0/en/Chinook-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html Chinook Therapeutics to Present at Upcoming Investor Conferences 2021-03-02T21:15:00Z 2021-03-03T02:16:58Z VANCOUVER, British Columbia and SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences:

]]>
2185725 en GlobeNewswire Inc. Chinook Therapeutics, Inc. Tue, 02 Mar 2021 21:15 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/03/02/2185698/0/en/Black-Diamond-Therapeutics-Announces-Pre-Clinical-Data-Presentations-on-New-Programs-Targeting-BRAF-and-FGFR-at-ESMO-TAT-Virtual-Congress-2021.html Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021 2021-03-02T21:05:00Z 2021-03-03T02:16:58Z CAMBRIDGE, Mass. and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data from two programs emerging from the Company’s proprietary MAP platform targeting BRAF and fibroblast growth factor receptor (FGFR) at the European Society of Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021, taking place March 1-2, 2021.

]]>
2185698 en GlobeNewswire Inc. Black Diamond Therapeutics, Inc Tue, 02 Mar 2021 21:05 GMT Calendar of Events Health
http://www.yebxqs.cn/news-release/2021/03/02/2185705/0/en/REMINDER-NextCure-to-Host-Virtual-R-D-Update-Event-on-March-4-2021.html REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021 2021-03-02T21:05:00Z 2021-03-03T02:16:58Z BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.

]]>
2185705 en GlobeNewswire Inc. NextCure Tue, 02 Mar 2021 21:05 GMT Calendar of Events Health
http://www.yebxqs.cn/news-release/2021/03/02/2185693/0/en/Sorrento-Receives-US-FDA-Clearance-to-Proceed-With-Phase-1-Study-for-STI-2099-Intranasal-COVIDROPS-in-Healthy-Volunteers-and-Outpatient-Treatment-for-Newly-Diagnosed-COVID-19-Posit.html Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients 2021-03-02T21:02:12Z 2021-03-03T02:16:58Z SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.?(Nasdaq: SRNE, “Sorrento”) announced today that it has received clearance from the FDA for its Investigational New Drug application (IND) for its Phase 1 study of the safety and pharmacokinetics of intranasal (IN) STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.

]]>
2185693 en GlobeNewswire Inc. Sorrento Therapeutics, Inc. Tue, 02 Mar 2021 21:02 GMT Health Sorrento Therapeutics COVIDROPS STI-2020 STI-2099 antibodies COVID COVID-19 SARS-CoV-2 Variants Mutation
http://www.yebxqs.cn/news-release/2021/03/02/2185690/0/en/Aptose-to-Release-Fourth-Quarter-and-Year-End-December-31-2020-Financial-Results-and-Hold-Conference-Call-on-March-23-2021.html Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021 2021-03-02T21:02:00Z 2021-03-03T02:16:58Z SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31, 2020, on Tuesday, March 23, 2021 after the close of the market.

]]>
2185690 en GlobeNewswire Inc. Aptose Biosciences, Inc. Tue, 02 Mar 2021 21:02 GMT Calendar of Events Aptose #aptose $apto
http://www.yebxqs.cn/news-release/2021/03/02/2185679/0/en/Genocea-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html Genocea to Present at the H.C. Wainwright Global Life Sciences Conference 2021-03-02T21:01:00Z 2021-03-03T02:16:58Z CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Tuesday, March 9, 2021 at 7:00 A.M. ET.

]]>
2185679 en GlobeNewswire Inc. Genocea Biosciences, Inc. Tue, 02 Mar 2021 21:01 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/03/02/2185680/0/en/NexImmune-to-Present-at-the-2021-Barclays-Global-Healthcare-Conference.html NexImmune to Present at the 2021 Barclays Global Healthcare Conference 2021-03-02T21:01:00Z 2021-03-03T02:16:58Z GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.?(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that?Scott Carmer, Chief Executive Officer, will present a company overview at the?virtual 2021 Barclays Global Healthcare Conference on?Thursday, March 11, 2021?at?10:55 a.m. Eastern time.

]]>
2185680 en GlobeNewswire Inc. NexImmune, Inc. Tue, 02 Mar 2021 21:01 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/03/02/2185669/0/en/Transactions-with-shares-and-linked-securities-in-Genmab-A-S-made-by-managerial-employees-and-their-closely-associated-persons.html Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 2021-03-02T20:31:47Z 2021-03-03T02:16:58Z Company Announcement

]]>
2185669 en GlobeNewswire Inc. Genmab A/S Tue, 02 Mar 2021 20:32 GMT Insider's Buy/Sell European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185668/0/en/Capital-Increase-in-Genmab-as-a-Result-of-Employee-Warrant-Exercise.html Capital Increase in Genmab as a Result of Employee Warrant Exercise 2021-03-02T20:26:50Z 2021-03-03T02:16:58Z Company Announcement

]]>
2185668 en GlobeNewswire Inc. Genmab A/S Tue, 02 Mar 2021 20:27 GMT Changes in share capital and votes European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185659/0/en/Global-WholeHealth-Partners-Corp-GWHP-OTC-to-Announce-That-the-Antibody-Test-Kits-Offered-by-Global-Can-Detect-the-S1-Protein-Used-in-COVID-19-Vaccines.html Global WholeHealth Partners Corp (GWHP-OTC) to Announce That the Antibody Test Kits Offered by Global Can Detect the S1 Protein Used in COVID 19 Vaccines 2021-03-02T19:31:59Z 2021-03-03T02:16:58Z People want to know if the vaccine worked; Global’s test will help people know if the IgG antibody is forming after the vaccine.

]]>
2185659 en GlobeNewswire Inc. Global WholeHealth Partners Corp. Tue, 02 Mar 2021 19:32 GMT Press releases
http://www.yebxqs.cn/news-release/2021/03/02/2185626/0/en/Transactions-in-connection-with-share-buyback-program.html Transactions in connection with share buyback program 2021-03-02T17:59:32Z 2021-03-03T02:16:58Z Company announcement no. 10 - 21
2 March 2021

]]>
2185626 en GlobeNewswire Inc. NTG Nordic Transport Group A/S Tue, 02 Mar 2021 17:59 GMT Changes in company's own shares European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185486/0/en/Cullinan-Oncology-Inc-to-Participate-in-the-H-C-Wainwright-Global-Life-Sciences-Conference.html Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference 2021-03-02T14:48:19Z 2021-03-03T02:16:58Z CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.

]]>
2185486 en GlobeNewswire Inc. Cullinan Management, Inc. Tue, 02 Mar 2021 14:48 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/03/02/2185461/0/en/BioCorRx-Completes-2-25-Million-Private-Placement.html BioCorRx Completes $2.25 Million Private Placement 2021-03-02T14:24:48Z 2021-03-03T02:16:58Z ANAHEIM, CA, March 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire?--?BioCorRx Inc. (OTCQB: BICX) (the “Company”),?a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that the Company completed a private placement, whereby it issued 1.125 million common stock shares at a price of $2.00 per share, for total proceeds of $2.25 million. The private placement was done with Louis Lucido and Joseph Galligan, both members of the Company’s Board of Directors.

]]>
2185461 en GlobeNewswire Inc. BioCorRx Inc Tue, 02 Mar 2021 14:25 GMT Financing Agreements
http://www.yebxqs.cn/news-release/2021/03/02/2185376/0/en/CohBar-to-Present-at-the-33rd-Annual-ROTH-Conference.html CohBar to Present at the 33rd Annual ROTH Conference 2021-03-02T14:00:00Z 2021-03-03T02:16:58Z MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will participate in a fireside chat with ROTH Senior Research Analyst Elemer Piros, Ph.D. at the 33rd Annual ROTH Conference, being held virtually March 15 – 17, 2021.

]]>
2185376 en GlobeNewswire Inc. CohBar, Inc. Tue, 02 Mar 2021 14:00 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/03/02/2185411/0/en/Innovation-Pharmaceuticals-Announces-Publication-of-Peer-Reviewed-Scientific-Article-in-the-Journal-Viruses-on-the-Anti-SARS-CoV-2-Properties-of-Brilacidin.html Innovation Pharmaceuticals Announces Publication of Peer-Reviewed Scientific Article in the Journal Viruses on the Anti-SARS-CoV-2 Properties of Brilacidin 2021-03-02T14:00:00Z 2021-03-03T02:16:58Z WAKEFIELD, MA, March 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the publication of a peer-reviewed scientific article—Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture—in the journal Viruses.

]]>
2185411 en GlobeNewswire Inc. Innovation Pharmaceuticals Inc. Tue, 02 Mar 2021 14:02 GMT Health Research Analysis and Reports ACE2 Receptor SARS-CoV-2 SARS coronavirus COVID-19
http://www.yebxqs.cn/news-release/2021/03/02/2185419/0/en/Sorrento-Receives-FDA-Clearance-to-Start-Clinical-Trial-of-Anti-CD47-Antibody-Discovered-from-Fully-Human-G-MAB-Library-for-Treatment-of-Multiple-Malignancies.html Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies 2021-03-02T14:00:00Z 2021-03-03T02:16:58Z SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has cleared Sorrento’s internally developed anti-CD47 monoclonal antibody, STI-6643, which was discovered from Sorrento's G-MAB? library, for an initial clinical trial. The initial clinical trial will be a basket trial entitled “A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Patients with Selected Relapsed or Refractory Malignancies.”??

]]>
2185419 en GlobeNewswire Inc. Sorrento Therapeutics, Inc. Tue, 02 Mar 2021 14:03 GMT Health Product / Services Announcement Research Analysis and Reports Sorrento Therapeutics CD-47 Malignancies Cancer Bucket Trial antibodies G-Mab
http://www.yebxqs.cn/news-release/2021/03/02/2185370/0/en/LIDDS-enters-R-D-agreement-with-potential-exclusive-global-product-license-option.html LIDDS enters R&D agreement with potential exclusive, global product license option 2021-03-02T13:50:00Z 2021-03-03T02:16:58Z UPPSALA, SWEDEN LIDDS AB (publ) announced today that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid? technology for an undisclosed indication.

]]>
2185370 en GlobeNewswire Inc. LIDDS AB Tue, 02 Mar 2021 13:50 GMT Company Announcement European Regulatory News
http://www.yebxqs.cn/news-release/2021/03/02/2185336/0/en/PsyBio-Therapeutics-Initiates-Pilot-Scale-Development-of-Proprietary-Biosynthetic-Psilocybin-with-Global-Contract-Research-Development-and-Manufacturing-Organization.html PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization 2021-03-02T13:30:25Z 2021-03-03T02:16:58Z OXFORD, Ohio and COCONUT CREEK, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio” or the “Company”), a leader in the field of psychedelic research and drug development, has initiated pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc. (“AMRI”), a leading global provider of advanced contract research, development and manufacturing solutions, with expertise in synthetic biology and fermentation development. The Company has completed Phase I of this process, including technology transfer activities, preparation of strain banks, and the adoption of analytical methods and looks forward to communicating additional progress.

]]>
2185336 en GlobeNewswire Inc. PsyBio Therapeutics Corp. Tue, 02 Mar 2021 13:31 GMT Product / Services Announcement
粉色午夜视频/色戒未删减版在线观看视频/44383x3全国最大的免费观看/冲田杏梨番号